The EAHP Board, elected for three-year terms, oversees the association’s activities. Comprising directors responsible for core functions, it meets regularly to implement strategic goals. Supported by EAHP staff, the Board controls finances, coordinates congress organization, and ensures compliance with statutes and codes of conduct.
10.6 EMA matters
Return to January 2016 Board Agenda here.
PRIME consultation
Consultation here. EAHP response here.
Orphan Drugs
Report from Marc Dooms from December workshop here. Agenda here.
Clinical Trials
Both Roberto and Francesca Venturini continue to input to the development of new trial databases and portals under the remit of the EMA, as well as advise on relevant EMA clinical trial related consultations.
To also note a future EMA workshop on extrapolation of efficacy and safety in medicine development in May 2016. Information here. Francesca advises appropriate HP representation.
Risk Minimisation
Among a number of working groups constructed by EMA through its stakeholder organisation is one focused on EMA’s activities around risk minimisation (e.g. communications) and assessment of their effectiveness. RP is currently the EAHP contact point in the working group. EMA are due to supply the group with some examples of such communications for members to comment on and review. Minutes of last teleconference here.
Shortages
EMA activity in the area of medicines shortages is covered in agenda item 10.2
EMA Leadership
Guido Rasi reinstated as Executive Director. Information here.